Vanda Pharma Q2 EPS $0.03 Beats $(0.13) Estimate, Sales $46.06M Miss $49.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Vanda Pharma reported Q2 earnings of $0.03 per share, beating the analyst consensus estimate of $(0.13) by 123.08 percent. However, this is a 40 percent decrease from the same period last year. The company's quarterly sales of $46.06 million missed the analyst consensus estimate of $49.00 million by 6.01 percent, marking a 28.47 percent decrease from the same period last year.
July 27, 2023 | 8:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vanda Pharma's Q2 earnings beat estimates but are down 40% YoY. Sales missed estimates and are down 28.47% YoY.
Vanda Pharma's earnings beat estimates, which is positive. However, the YoY decrease in both earnings and sales, as well as the missed sales estimates, are negative indicators that could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100